Recent Updates
Recently added Catalysts
LFMD Positive Sentiment Score: 75/100

LifeMD, Inc. Announces Closing of New $40 Million Credit Facility

Key Takeaway: LifeMD, Inc. has successfully closed a $40 million senior secured credit facility with Avenue Capital, which matures on October 1, 2026. This financing consists of an initial $15 million term loan, with provisions for additional capital in the future. Management expresses confidence that this funding will enhance the company's financial flexibility and support their strategic growth initiatives. The credit facility is secured by a lien on most of the company's assets and includes an 18-month interest-only period.

Market Sentiment Analysis

POSITIVE FACTORS

  • LifeMD has secured a new $40 million credit facility with Avenue Capital.
  • The financing is expected to strengthen LifeMD's balance sheet and support long-term growth plans.
  • Investment from Avenue Capital validates the strength of LifeMD's business and long-term outlook.

Full Press Release Details

Inc. Announces Closing of New $40 Million Credit Facility
YORK, March 22, 2023 - LifeMD,
Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that the Company closed on a new senior secured
credit facility with Avenue Capital. The credit agreement, which matures on October 1, 2026, provides up to $40 million in total term
loan capital including a first tranche of $15 million funded at closing, a second tranche of $5 million of committed capital and an additional
accordion option to upsize the credit facility by an additional $20 million.
are very pleased to secure this financing and excited to partner with a leading institutional investor, Avenue Capital, as we continue
to execute upon our strategic growth and profitability plans," said Justin Schreiber, Chairman & CEO, LifeMD. "This financing
strengthens our balance sheet and provides LifeMD with what we believe to be more than sufficient capital to meet our long-term needs.
We believe Avenue's decision to invest in LifeMD is a testament to the strength of our current business and our long-term outlook."
CFO Marc Benathen, commented "This financing provides LifeMD with important, minimally dilutive capital to meet our long-term needs.
By combining this capital with the Company's expectation of a near-term elimination of our cash burn, we believe LifeMD is now
capitalized to execute against our strategic plans with an enhanced level of financial flexibility. The investment from a leading institution,
Avenue Capital, further validates the strength of our Company. Lastly, this investment affords LifeMD the opportunity to retain its majority
interest in WorkSimpli which we believe to be substantially accretive to shareholder value and expect WorkSimpli to generate 20%+ EBITDA
term loans provide for an 18-month interest-only period, which can be extended to 24 months upon satisfaction of certain conditions.
The second tranche will be available for draw at the Company's election in the fourth quarter 2023 provided the Company is in compliance
with the agreement. The additional accordion option is available subject to mutual approval by the Company and Avenue Capital. The credit
facility bears interest at an annual rate equal to the greater of (i) the sum of four and three-quarters percent (4.75%) plus the Prime
Rate, and (ii) twelve and one-half percent (12.50%). The obligations under the Avenue Capital credit facility are secured by a lien on
substantially all of the assets of the Company.
Company also issued warrants with an exercise price of $1.24 per share to purchase up to 967,742 shares of its common stock to Avenue
is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized
treatment for men's and women's health, allergy & asthma, and dermatological conditions. By leveraging its proprietary
technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch
healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Note Regarding Forward Looking Statements
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe,"
"expect," "anticipate," "project," "should," "plan," "will,"
"may," "intend," "estimate," predict," "continue," and "potential,"
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.

Frequently Asked Questions

What is the total amount of the new credit facility secured by LifeMD?

LifeMD secured a new credit facility totaling up to $40 million.

Who is the institutional investor that partnered with LifeMD?

LifeMD partnered with Avenue Capital as their institutional investor.

What is the maturity date of LifeMD's new credit agreement?

The credit agreement matures on October 1, 2026.

What will the second tranche of the loan be available?

The second tranche of $5 million will be available in Q4 2023 if compliant.

How does this financing impact LifeMD's financial flexibility?

This financing enhances LifeMD's financial flexibility to execute their strategic plans.

Last updated: Mar 22, 2023